

FT3 Country Pilots Impact Overview

From global learnings to local impact and beyond



Background

Precision medicine (PM) has the potential to transform lives, but it has not yet become a reality for many patients who could benefit from it. Scaling access to precision medicine is highly fragmented across countries and conditions. Patients' ability to access precision medicine differs from one region or country to another. Even in countries where precision medicine is reimbursed, some patients who could benefit from personalized treatment do not get access or have a suboptimal care experience.



The From Testing to Targeted Treatments (FT3) program community has co-created practical tools for “champions” of precision medicine (e.g. patient advocates, ambassadors from the healthcare community, etc.) to help drive change. FT3 created a Country Pilot program to support local champions further. The goals of the Country Pilot Program are:

- Share global learnings from the FT3 community, including through a Community of Practice, to share experiences and **support local champions/advocates** in improving access to PM
- **Learn about (local) barriers and solutions** to make PM more accessible to patients, learn about how to apply & improve FT3 tools locally to accelerate access
- Develop case studies to **share learnings & good practices** with the wider PM community

The country pilot program contributes to the FT3 strategy. Each pilot aims to address one or more goals and strategic drivers to accelerate access to precision medicine for those who can benefit from it.

2023 Impact Overview

The overview below showcases high-level achievements of the first phase of the country pilots program. These pilots will continue and expand in 2024.

Global program



2 country pilots have launched, and 4 country pilots are in incubation

3 virtual global Community of Practice meetings supporting advocates with accelerating access to PM.

5 guest speakers shared their learnings and experiences covering a range of topics and 4 condition areas

1 in-person workshop in Madrid. 34 participants across the globe shared learnings from pilots and how to apply the group's collective intelligence to respond to common access challenges across 4 topic areas

Spain

Accelerate efforts to address structural barriers to PM, Increase patient awareness and support patient empowerment

160 patients, of which 120 had biomarker testing, answered a nationwide survey on knowledge of biomarker testing. The results highlight patient information needs and experiences with biomarker testing in Spain

33 HCPs answered a survey about access to PM. Results show regional disparities in access and differences in system readiness

1 Spain lung cancer card showing the availability of biomarker testing & treatment, clinical guidelines, and hospitals 3 regional lung cancer cards showing the access situation in Cantabria, Catalonia and Andalusia

Hungary

Increase patient awareness and support patient empowerment, Support HCPs and clinical shared decision-making

7 lay language resources were made available to HCPs in Hungary to hand out to patients.

1 Hungary Country Card for Lung Cancer provided a framework for addressing the specific challenges and requirements of the region

3 workshops with 50+ HCPs at conferences and hospitals showcased the new resources to support HCPs in explaining to patients their treatment and providing the right information at the right time

Outreach efforts have reached more than 100 patients and 50+ HCPs in Hungary

Feedback from patients confirms an increase in patient confidence when communicating with healthcare professionals about precision medicine

The feedback received after 3 workshops with healthcare providers, hospitals and centers, shows the usefulness of the new resources to support HCPs in explaining to patients their treatment and providing the right information at the right time.



Systemic impact and amplification

The country pilots initiative approach not only applies global learnings for local impact, it also generates new learnings that can be scaled and translated to other similar PM contexts to accelerate change. Here are some opportunities to translate local successes to other regions and examples of good practice sharing already in progress.

The Spanish patient survey has been translated into English and used by COR2ED in their global survey, which was translated into 3 additional languages (French, Portuguese and Traditional Chinese)

The Spanish case study can be used as a model for other advocates in countries with decentralized health systems, seeking to collect information about access barriers and inequalities to accelerate efforts to address structural barriers to PM

FT3 adaptable resources will be translated into 7 other languages (Spanish, Portuguese, Polish, Japanese, French, German, and Italian) to empower patients in other countries.

FT3 educational resources adapted by the Hungarian team provided learnings on how local POs can use the co-created FT3 resources in practice to help educate patients and HCPs for more informed shared decision-making. The adaptations to fit the Hungarian context provide helpful feedback to improve the original resource

The Hungarian approach is scalable to other countries that seek to increase patient awareness, support patient empowerment, and support HCPs and clinical shared decision-making. Other countries currently being explored include Japan, the Philippines and Mexico.



It was a great experience because we made a strong team. There were representatives of patients, industry representatives and also doctors. I think we already made a huge impact by working together to improve lung cancer care in Hungary. And we got feedback from doctors and patients too. They found our materials very helpful.



Dr. Eszter Czibula

There were different stakeholders from different functions. There were physicians, nurses, patient advocates involved in this project, as well as industry players. It was great to see the synergy that was created with the good intentions of those stakeholders working on the same objective.



Tugba Camli Canturk

We made a huge impact by working together to improve Hungarian lung cancer care. It was a really nice experience for me as a doctor to work in a group like this, with representatives, patients, and people who are trying to help patients as well as our colleagues



Dr. Eszter Czibula

We have embraced this project since the beginning of June 2022, because we all serve the same mission which is to ensure that people with lung cancer in Spain who could benefit from precision medicine, especially biomarker testing, have equal access to this progress within the public healthcare system.



Diego Villalón